GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Diagnostics & Research » Verici Dx PLC (OTCPK:VRCDF) » Definitions » Total Debt per Share

VRCDF (Verici Dx) Total Debt per Share : $0.00 (As of Jun. 2024)


View and export this data going back to 2021. Start your Free Trial

What is Verici Dx Total Debt per Share?

$0.00 (As of Jun. 2024)

Total Debt per Share is calculated as total debt divided by Shares Outstanding (EOP). Total debt is calculated as Long-Term Debt & Capital Lease Obligation plus Short-Term Debt & Capital Lease Obligation. Verici Dx's Total Debt Per Share for the quarter that ended in Jun. 2024 was $0.00.


Verici Dx Total Debt per Share Historical Data

The historical data trend for Verici Dx's Total Debt per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Verici Dx Total Debt per Share Chart

Verici Dx Annual Data
Trend Dec20 Dec21 Dec22 Dec23
Total Debt per Share
- - - -

Verici Dx Semi-Annual Data
Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24
Total Debt per Share Get a 7-Day Free Trial - - - - -

Verici Dx Total Debt per Share Calculation

Verici Dx's Total Debt Per Share for the fiscal year that ended in Dec. 2023 is calculated as:

Verici Dx's Total Debt Per Share for the quarter that ended in Jun. 2024 is calculated as:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Verici Dx Total Debt per Share Related Terms

Thank you for viewing the detailed overview of Verici Dx's Total Debt per Share provided by GuruFocus.com. Please click on the following links to see related term pages.


Verici Dx Business Description

Traded in Other Exchanges
Address
19 Stanwell Road, Avon House, Penarth, Cardiff, GBR, CF64 2EZ
Verici Dx PLC is an immuno-diagnostics development company. The company is focused on developing diagnostics technologies that will help understand the outcomes of an organ transplant surgery. There are two products for clinical validation and commercialization: Clarava, which is a pre-transplant prognosis for the risk of early acute rejection; and Tuteva, a post-transplant diagnostic focused upon acute cellular rejection including sub-clinical rejection not being diagnosed through the current standard of care of rising serum creatine levels. The business of the Group comprises a single activity, which of the development of prognostic and diagnostic tests for kidney transplant patients.

Verici Dx Headlines

No Headlines